Eliem Therapeutics Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	4.6yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Feb 01

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

Jun 24

CEO

Eliem Therapeutics no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Andrew Levin	Principal Financial Officer & Executive Chairman	5.3yrs	US$96.34k	sin datos
Valerie Morisset	Chief Scientific Officer and Executive VP of Research & Development	5.1yrs	US$1.99m	1.8% $ 3.8m
Emily Pimblett	Chief Accounting Officer	1.3yrs	sin datos	sin datos
Jo Palmer-Phillips	Chief Development Officer	no data	sin datos	sin datos

1.3yrs

Permanencia media

45yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ELYM no se considera experimentado ( 1.2 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Andrew Levin	Principal Financial Officer & Executive Chairman	5.3yrs	US$96.34k	sin datos
Adam Rosenberg	Independent Director	3.6yrs	US$70.84k	0.64% $ 1.3m
Liam Ratcliffe	Lead Independent Director	4.6yrs	US$68.34k	0% $ 0
Simon Tate	Independent Director	5.3yrs	US$23.34k	0% $ 0
Judith Dunn	Independent Director	3.3yrs	US$63.34k	0% $ 0

4.6yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: La junta directiva de ELYM se considera experimentada (4.5 años de antigüedad promedio).

Eliem Therapeutics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Eliem Therapeutics, Inc. and Tenet Medicines, Inc. Announces Management and Organization Changes

Insufficient new directors

Bob Azelby to Depart as Chief Executive Officer of Eliem Therapeutics, Inc

Eliem Therapeutics, Inc. Announces the Resignation of Leone Patterson from the Board of Directors

Eliem Therapeutics, Inc., Annual General Meeting, May 19, 2022

Eliem Therapeutics, Inc. Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs

Recent updates

Eliem Therapeutics, Inc. announced that it expects to receive $119.955003 million in funding from RA Capital Management, L.P., Deep Track Capital, LP, Boxer Capital LLC, Samsara BioCapital LLC, Janus Henderson Investors US LLC

New major risk - Share price stability

Eliem Therapeutics, Inc. and Tenet Medicines, Inc. Announces Management and Organization Changes

Insufficient new directors

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

New minor risk - Shareholder dilution

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Bob Azelby to Depart as Chief Executive Officer of Eliem Therapeutics, Inc

Eliem Therapeutics, Inc. Announces the Resignation of Leone Patterson from the Board of Directors

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Price target decreased to US$6.00

Eliem Therapeutics, Inc. Provides Update on Pipeline Progress

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Eliem Therapeutics, Inc. Provides ETX-810 Program Update

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating

Eliem Therapeutics, Inc. Announces Last Patient Completed Dosing in Phase 2A Study of ETX-810 in Patients with Lumbosacral Radicular Pain

Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from Russell 2500 Value Index

Eliem Therapeutics Reports Results from its Phase 2A Clinical Trial Investigating ETX-810 for the Treatment of Diabetic Peripheral Neuropathic Pain and Provided an Update on the Status of the ETX-155 Clinical Program in Epilepsy and Depression

Eliem Therapeutics, Inc., Annual General Meeting, May 19, 2022

Eliem Therapeutics, Inc. Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs

High number of new directors

High number of new and inexperienced directors

Eliem Therapeutics, Inc. has completed an IPO in the amount of $80 million.

CEO

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad